178 related articles for article (PubMed ID: 36329471)
1. Taking the cat-and-mouse game to the next level: different perspectives on the introduction of the German New Psychoactive Substances Act.
Kühnl R; Aydin D; Horn S; Olderbak S; Verthein U; Kraus L
Harm Reduct J; 2022 Nov; 19(1):122. PubMed ID: 36329471
[TBL] [Abstract][Full Text] [Related]
2. Legal Approaches to New Psychoactive Substances: First Empirical Findings.
van Amsterdam J; Burgess N; van den Brink W
Eur Addict Res; 2023; 29(5):363-372. PubMed ID: 37557091
[TBL] [Abstract][Full Text] [Related]
3. What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, 'legal highs')? Implications for law enforcement and penalties.
Rychert M; Wilkins C
Drug Test Anal; 2016 Aug; 8(8):768-78. PubMed ID: 26857892
[TBL] [Abstract][Full Text] [Related]
4. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
Rychert M; Wilkins C
Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
[TBL] [Abstract][Full Text] [Related]
5. Current challenges and problems in the field of new psychoactive substances in Germany from a law enforcement perspective.
Duffert A
Drug Test Anal; 2014; 6(7-8):876-8. PubMed ID: 24415657
[TBL] [Abstract][Full Text] [Related]
6. Scheduling of new psychoactive substance the Swiss way: A review and critical analysis.
Grafinger KE; Bernhard W; Weinmann W
Sci Justice; 2019 Jul; 59(4):459-466. PubMed ID: 31256819
[TBL] [Abstract][Full Text] [Related]
7. Effect of new legislation in Germany on prevalence and harm of synthetic cannabinoids.
Sommer MJ; Halter S; Angerer V; Auwärter V; Eyer F; Liebetrau G; Ebbecke M; Hermanns-Clausen M
Clin Toxicol (Phila); 2022 Oct; 60(10):1130-1138. PubMed ID: 36074033
[TBL] [Abstract][Full Text] [Related]
8. Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016.
Deen AA; Claridge H; Treble RD; Hamnett HJ; Copeland CS
J Psychopharmacol; 2021 Nov; 35(11):1315-1323. PubMed ID: 34182812
[TBL] [Abstract][Full Text] [Related]
9. New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?
Napoletano S; Basile G; Lo Faro AF; Negro F
Acta Biomed; 2022 May; 93(2):e2022186. PubMed ID: 35545997
[TBL] [Abstract][Full Text] [Related]
10. New psychoactive substances legislation in Ireland - Perspectives from academia.
Kavanagh PV; Power JD
Drug Test Anal; 2014; 6(7-8):884-91. PubMed ID: 24478277
[TBL] [Abstract][Full Text] [Related]
11. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
12. Monitoring new psychoactive substances: Exploring the contribution of an online discussion forum.
Rhumorbarbe D; Morelato M; Staehli L; Roux C; Jaquet-Chiffelle DO; Rossy Q; Esseiva P
Int J Drug Policy; 2019 Nov; 73():273-280. PubMed ID: 30967328
[TBL] [Abstract][Full Text] [Related]
13. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
Van Hout MC; Hearne E
Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
[TBL] [Abstract][Full Text] [Related]
14. A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand.
Wilkins C
Addiction; 2014 Oct; 109(10):1580-6. PubMed ID: 24529166
[TBL] [Abstract][Full Text] [Related]
15. Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONE.
Angerer V; Mogler L; Steitz JP; Bisel P; Hess C; Schoeder CT; Müller CE; Huppertz LM; Westphal F; Schäper J; Auwärter V
Drug Test Anal; 2018 Mar; 10(3):597-603. PubMed ID: 28670781
[TBL] [Abstract][Full Text] [Related]
16. Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan.
Kikura-Hanajiri R; Kawamura NU; Goda Y
Drug Test Anal; 2014; 6(7-8):832-9. PubMed ID: 24573957
[TBL] [Abstract][Full Text] [Related]
17. New Psychoactive Substances: A Potential Threat to Developing Countries.
Hasan M; Sarker SA
Addict Health; 2023 Apr; 15(2):136-143. PubMed ID: 37560390
[TBL] [Abstract][Full Text] [Related]
18. The challenge of a ban on animal testing for the development of a regulated legal market for new psychoactive substances (NPS) ('legal highs') in New Zealand: Issues and options for resolution.
Rychert M; Wilkins C
Int J Drug Policy; 2015 Dec; 26(12):1273-8. PubMed ID: 26364077
[TBL] [Abstract][Full Text] [Related]
19. Issues with monitoring the safety of psychoactive products under a legal regulated market for new psychoactive substances ('legal highs') in New Zealand.
Rychert M; Wilkins C; Witten K
Drug Alcohol Rev; 2017 Sep; 36(5):589-596. PubMed ID: 28229493
[TBL] [Abstract][Full Text] [Related]
20. [Legislation of New Psychoactive Substances in the Netherlands].
Smit-Rigter LA; Van Laar MW
Ned Tijdschr Geneeskd; 2021 Nov; 165():. PubMed ID: 34854638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
